CINGULATE INC. CING 深 滬
等待開盤 12-12 09:30:00 美东时间
4.18
+0.230
+5.82%
華盛通- 最 高4.18
- 今 開3.98
- 成交量 20.95万股
- 最 低 3.86
- 昨 收 3.95
- 總市值 2343.31万
- 52周最高 6.01
- 市盈率 靜 --
- 換手率 3.74%
- 52周最低 3.20
- 委 比 -85.16%
- 總股本 560.60万
- 歷史最高 1236.00
- 量 比 1.89
- 振 幅 8.10%
- 歷史最低 2.574
- 每 手 1
- 風險率 0.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Ascendiant Capital Maintains Buy on Cingulate, Lowers Price Target to $58
Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $62 to $58.
12-08 18:19
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
Roth Capital Maintains Buy on Cingulate, Lowers Price Target to $16
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $17 to $16.
11-20 02:00
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
Cingulate Inc.'s CTx-1301, a once-daily dexmethylphenidate, met its primary endpoint in a Phase 3 trial, showing significant improvements in ADHD symptoms in children and adolescents with consistent relief up to 12 hours. The study demonstrated rapid onset and sustained efficacy, with a favorable safety profile. The drug, utilizing Precision Timed Release™ technology, aims to simplify treatment and improve adherence with once-daily dosing. The Ne...
10-28 12:00
Cingulate's Data From Lead ADHD Candidate CTx-1301 Selected For Podium Presentation At AACAP Annual Meeting In Chicago
Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™)
10-24 04:48
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Cingulate Inc. announced that data from its ADHD candidate CTx-1301, a once-daily extended-release formulation, will be presented at the AACAP Annual Meeting. Dr. Ann Childress, a leading ADHD expert, will present Phase 3 findings highlighting CTx-1301’s potential to provide full-day symptom control. The presentation underscores the scientific interest in CTx-1301, designed to address limitations of current stimulant therapies. Results will be li...
10-23 20:45
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
Roth Capital Maintains Buy on Cingulate, Raises Price Target to $17
Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10 to $17.
10-16 01:49
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 46.4% to $0.37 during Tuesday...
10-15 05:06
